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Nonalcoholic fatty liver disease (NAFLD) is the principal manifestation of liver disease in obesity and metabolic syndrome.
By comparing hypertriglyceridemic transgenic mice expressing apolipoprotein (apo) CIII with control nontransgenic (NTg)
littermates, we demonstrated that overexpression of apoCIII, independent of a high-fat diet (HFD), produces NAFLD-like
features, including increased liver lipid content; decreased antioxidant power; increased expression of TNF𝛼, TNF𝛼 receptor,
cleaved caspase-1, and interleukin-1𝛽; decreased expression of adiponectin receptor-2; and increased cell death. This phenotype is
aggravated and additional NAFLD features are differentially induced in apoCIII mice fed a HFD. HFD induced glucose intolerance
together with increased gluconeogenesis, indicating hepatic insulin resistance. Additionally, the HFD led to marked increases in
plasma TNF𝛼 (8-fold) and IL-6 (60%) in apoCIII mice. Cell death signaling (Bax/Bcl2), effector (caspase-3), and apoptosis were
augmented in apoCIII mice regardless of whether a HFD or a low-fat diet was provided. Fenofibrate treatment reversed several of
the effects associated with diet and apoCIII expression but did not normalize inflammatory traits even when liver lipid content was
fully corrected. These results indicate that apoCIII and/or hypertriglyceridemia plays a major role in liver inflammation and cell
death, which in turn increases susceptibility to and the severity of diet-induced NAFLD.
1. Introduction
Hypertriglyceridemia is a common condition caused bymul-
tiple environmental and genetic factors [1, 2]. Elevated
plasma levels of triglyceride- (TG-) rich remnant lipopro-
teins are independent risk factors for cardiovascular disease
(CVD) [3]. Clinical and experimental studies have shown
strong correlations and causal links between plasma TG and
apolipoprotein CIII (apoCIII) levels [4, 5]. Plasma apoCIII
levels are also increased in individuals with diabetes [6, 7].
Moreover, loss-of-functionmutations in the apoCIII gene are
associated with low TG levels and a reduced risk of CVD
[8, 9]. Therefore, TG levels are causally linked to apoCIII and
CVD, and apoCIII inhibitors are already in clinical develop-
ment to reduce CVD risk [10].
Hypertriglyceridemia and nonalcoholic fatty liver disease
(NAFLD) are common features in obesity andmetabolic syn-
drome [11]. The prevalence of NAFLD in western countries
ranges from 25 to 35% [12], and liver steatosis is observed in
80% of individuals with obesity [13]. Hepatic insulin resis-
tance and type II diabetes are considered sequelae of NAFLD
[14]. Furthermore, persistent steatosis may progress to steato-
hepatitis (NASH), cirrhosis, and hepatocarcinoma [15].
The two-hit hypothesis [16] has been proposed to explain
NAFLD pathogenesis. In this hypothesis, steatosis represents
the “first hit.” Steatosis increases the vulnerability of the liver
to various “second hits” that in turn lead to inflammation,
fibrosis and cellular death. Oxidative stress is one such second
hit. The inflammatory response, including the production of
numerous proinflammatory molecules and adipokines, also
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has a key role in the initiation and progression of the disease
[17]. Proinflammatory cytokines can cause liver damage
either directly or indirectly by increasing oxidative stress; in
turn, oxidative stress can impair liver function either directly
or indirectly by perpetuating a vicious cycle [18]. The path-
ways that control oxidative stress and inflammation underlie
many cardiometabolic diseases, including obesity, diabetes,
and atherosclerosis. Accordingly, recent evidence suggests
that the morbidity and mortality associated with NAFLD are
not restricted to changes in the liver, as the majority of deaths
of patients with NAFLD are related to CVD [19].
We previously demonstrated that hypertriglyceridemic
transgenic mice overexpressing apoCIII exhibit increases in
hepatic glycerolipid content and liver oxidative stress.The lat-
ter was associated with increased NADPH oxidase and xan-
thine oxidase activities, even when the mice consumed a reg-
ular low-fat diet (LFD) [20]. Another recent study reported
that apoCIII-overexpressingmice developNAFLDassociated
with severe hepatic insulin resistance, increased liver lipid
uptake and decreased lipid secretion following consumption
of a high-fat diet (HFD) [21].
The present study was designed to investigate whether
apoCIII overexpression and/or the resulting hypertriglyc-
eridemia trigger the main events driving the evolution of
steatosis to NASH, namely, inflammation and cell death. Fur-
thermore, we tested whether the PPARa agonist fenofibrate,
which regulatesmany genes related to inflammation and lipid
metabolism, including apoCIII, could reduce susceptibility to
NAFLD.
2. Materials and Methods
2.1. Animals and Treatments. All experimental protocols for
this study were approved by the university’s Committee for
Ethics in Animal Experimentation (CEUA/UNICAMP, pro-
tocol number 2436), and the research was conducted in
conformity with the Public Health Service Policy. Male mice
transgenic for human apoCIII and nontransgenic controls
were maintained at the Division of Physiology and Bio-
physics, Biology Institute, State University of Campinas (Sa˜o
Paulo, Brazil). Human apoCIII transgenic founder mice (line
3707) [22] were donated by Dr. Alan R. Tall (Columbia
University, New York, NY) in 1996 and have since been
crossbred with wild-type (NTg) C57BL/6 mice (Multidis-
ciplinary Center for Biological Research of the University
of Campinas). The apoCIII transgenic mice were screened
according to their fasting TG plasma levels (apoCIII mice >
300mg/dL; control mice < 100mg/dL) and housed in a room
at 22∘C ± 2∘C with a 12-hour light-dark cycle with free access
towater and food.One-month-oldmalemice (transgenic and
NTg littermates) were fed either a LFD or a HFD until 4
months of age. Additional groups of mice fed a HFD were
treated with fenofibrate (100mg/kg bw, Allergan, SP, Brazil,
solubilized in 5% Arabic gum) or 5% Arabic gum (control
untreated group) during the last 2 weeks of HFD consump-
tion by daily gavage. At 4 months of age, fasted mice were
anesthetized via intraperitoneal (IP) injection of ketamine
and xylazine (50 and 10mg/kg) and euthanized by exsan-
guination through the retro-orbital plexus (see Table 1).
2.2. Biochemical Analyses. Plasma levels of total cholesterol,
triglycerides (Chod-Pap; Roche Diagnostic GmbH, Mann-
heim, Germany), nonesterified fatty acids (Wako Chemical,
Neuss, Germany), and liver transaminases (Biotecnica, SP,
Brazil) were assayed using enzymatic-colorimetric methods
according to the manufacturers’ instructions. Leptin, adipo-
nectin (Merck Millipore, Darmstadt, Germany), C-reactive
protein (IBL-America, Minneapolis, USA), TNF𝛼, and IL-
1𝛽 (R&D Systems, Minneapolis, USA) plasma concentrations
were determined using ELISA. For analysis of IL-1𝛽 expres-
sion in liver tissue, 50-mg tissue samples were homogenized
in 2mL Lysis Buffer 2 (R&D Systems, Minneapolis, USA).
IL-6 plasma levels were analyzed using a Multiplex Assay
(Merck Millipore, Darmstadt, Germany). Protein carbonyl
content in the liver was measured using a colorimetric assay
kit (Cayman Chemical Company, Michigan, USA).
2.3. Levels of Reduced and Oxidized Glutathione in Liver and
Plasma. Liver (50mg) and plasma (50 𝜇L) levels of reduced
glutathione (GSH) and oxidized glutathione (GSSG) were
assayed separately according to the fluorometric orthophtha-
laldehyde (OPT) method reported by Hissin and Hilf [23].
This method is based on the fact that OPT reacts with GSH
and GSSG at pH 8.0 and pH 12, respectively, to yield a highly
fluorescent product that can be activated at 350 nm with an
emission peak of 420 nm. GSSG levels were determined after
sample treatment with N-ethylmaleimide to ensure complete
removal of GSH. The concentrations of GSH and GSSG
in samples were calculated according to standard curves
individually prepared with GSH and GSSG.
2.4. Liver Triglyceride Content. Liver lipids were extracted
using the Folch [24] method. The lipid extracts were resus-
pended in Triton buffer (20mL of 0.5M potassium phos-
phate, pH 7.4, 0.25M NaCl, 25mM cholic acid, 0.5% Triton
X-100), and TG levels were determined using an enzymatic-
colorimetricmethod according to themanufacturer’s instruc-
tions (Chod-Pap; RocheDiagnostic GmbH,Mannheim, Ger-
many).
2.5. Liver Histological Analysis. Liver tissue samples were
taken from the left lobe and incubated in 10% phosphate-
buffered formaldehyde at room temperature overnight. The
samples were then washed 3 times with phosphate-buffered
saline (PBS) and fixed in 70% ethanol. After fixation, the
tissues were embedded in paraffin, sectioned to a thickness
of 5 𝜇m and stained with hematoxylin-eosin (HE).
2.6. Oil Red O Staining. Liver samples were fixed in 4%
formaldehyde, washed with PBS, embedded in Tissue-Tek
OCT embedding compound, and frozen.The frozen sections
(10 𝜇m thick) were rehydrated, and neutral lipid accumula-
tion was detected by Oil Red O staining. Then, the sections
were rinsedwith 60% isopropanol and stained for 18minwith
prepared Oil Red O solution (0.5% in isopropanol followed
by dilution to 60% with distilled water and filtration). Slides
were washed twice in 60% isopropanol and distilled water.
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Table 1: Diet composition (g/100 g).
Diet Protein Fat Carbohydrate Fiber Calories (Kcal/100 g)
Low fat 14 4 (9.5% of calories) 72 5 380
High fat 14 35 (59% of calories) 41 5 536
Note. The basis of both the low-fat and high-fat diets is AIN-93.
Digital images were takenwith anOlympus BX51microscope
connected to an Olympus DP72 digital camera.
2.7. Immunofluorescence Microscopy. Liver sections were
fixed in 4%paraformaldehyde in PBS for 30min at room tem-
perature and then washed with PBS. Nonspecific binding was
blocked by incubation with 5% bovine serum albumin (BSA)
in PBS for 1 h.The sections were then incubated with primary
antibodies specific for TNFR1 (1 : 50, Santa Cruz Biotech-
nology) or IL1𝛽 (1 : 100, Cell Signaling) overnight (4∘C), fol-
lowed by incubation with a primary antibody against CD68
(1 : 250, Serotec) for 3 h (room temperature). Next, the tissue
sections were incubated with Alexa Fluor-labeled secondary
antibodies (Invitrogen) for 1 h (room temperature). Pictures
were taken on a Leica DMI600Bmicroscope, and colocalized
areas in random fields (1 per section/mouse) were analyzed
using ImageJ software.
2.8. Analysis of Apoptosis. Apoptosis was analyzed via the ter-
minal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) method using an in situ cell detection kit (Roche
Diagnostics). Nuclei were labeled with 4󸀠,6-diamidino-2-
phenylindole (DAPI; Sigma Aldrich). Only TUNEL-positive
cells that colocalized with DAPI-stained nuclei were consid-
ered apoptotic and counted. Random fields (5 per section) of
10 𝜇m were counted for each mouse.
2.9. Oral Glucose Tolerance Test and Insulin Tolerance Test.
For the oral glucose tolerance test (OGTT), after 12 hours
of fasting, mice received an oral dose of glucose solution
(1.5 g/kg body weight). Basal blood samples were collected
from the tail tip before (𝑡 = 0min) and 15, 30, 60, and 90min
after glucose ingestion. For the insulin tolerance test (ITT),
mice were fasted for three 3 hours, and blood samples were
collected immediately before IP insulin injection [0.75U/Kg
body weight of regular human insulin (Eli Lilly Co.)] and at 5,
10, 15, 30, and 60min after injection for glucose analysis.
Blood glucose concentrations were measured using a glucose
analyzer (Accu-Chek Advantage, Roche Diagnostic, Switzer-
land).
2.10. Pyruvate-Derived Glucose Production Test. After 16
hours of fasting, mice were injected with a pyruvate solution
(1.5 g/kg bodyweight). Blood sampleswere collected from the
tail tip before (𝑡 = 0min) and 15, 30, 60, and 90min after the
injection. Blood glucose concentrations weremeasured using
a glucose analyzer (Accu-ChekAdvantage, RocheDiagnostic,
Switzerland).
2.11. Analysis of Liver Very Low-Density Lipoprotein-Triglyc-
eride Secretion. After 12 h of fasting, basal blood samples
were collected frommice via the tail tip (𝑡 = 0min).Then, the
mice received an IP injection of Triton WR 1339 (500mg/kg
in saline solution; Sigma) to inhibit lipoprotein lipase activity
as well as TG hydrolysis and clearance. Additional blood
samples were collected at 120 and 150 minutes after Tri-
ton injection. For analysis of very low-density lipoprotein-
(VLDL-) TG secretion, plasma TG levels were determined
using an enzymatic-colorimetric assay according to the
manufacturer’s instructions (Chod-Pap; Roche Diagnostic
GmbH, Mannheim, Germany).
2.12. RNA Extraction and Real-Time Reverse Transcription
PCR. Total liver RNA was extracted from approximately
50mg of tissue using TRIzol reagent (Invitrogen, Grand
Island, NY, USA). RNA integrity was assessed using Tris-
borate 1.2% agarose gels stainedwith ethidiumbromide. RNA
quantity and purity were measured via optical density read-
ings taken at 260 and 280 nm (GeneQuant, Amersham-Phar-
macia Biotech). Genomic DNA contamination was excluded
by running polymerase chain reaction (PCR) on the RNA
samples. cDNA was prepared in duplicate from 2𝜇g of total
RNA via reverse transcription using an Applied Biosystems
High-Capacity cDNA Reverse Transcription Kit according
to the manufacturer’s instructions. Gene expression was
determined using real-time reverse transcription polymerase
chain reaction (RT-PCR) (Step One Real-time PCR System,
Applied Biosystems, Foster City, CA, USA) with SYBRGreen
PCR Master Mix and specific primers. The ΔΔCT method
was used to quantify gene expression. The threshold cycle
was normalized to 𝛽-actin and then expressed relative to the
control groups (see Table 2).
2.13. Western Blotting. Liver tissue samples were homoge-
nized in urea lysis buffer (2M thiourea, 5mM EDTA, 1mM
sodium fluoride, 1mM sodium orthovanadate, 1mM sodium
pyrophosphate, 1% aprotinin, 2mM PMSF, and 1% Triton-X
100), and protein concentrations were determined using the
Bradford [25] method. Forty-microgram samples of protein
lysate were resolved on SDS-polyacrylamide gels, transferred
to nitrocellulose membranes and stained with Ponceau S
(Sigma) to verify transfer efficiency and equal sample loading.
The membranes were blocked with 5% albumin in Tris-HCl
pH 7.6 containing 150mM sodium chloride and 0.1% Tween-
20 (TBST) and incubated for 2 hours at room temperature
with antibodies against caspase-1 (1 : 500, Abcam), caspase-3
(1 : 100, Santa Cruz Biotechnology), Bcl2 (1 : 1000, Cell Sig-
naling), or Bax (1 : 1000, Cell Signaling). An antibody against
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Table 2: Primer sequences used for RT-PCR.
Genes Primers
𝛽-Actin Forward 5
󸀠 GGACTCATCGTACTCCTGCTT 3󸀠
Reverse 5󸀠 GAGATTACTGCTCTGGCTCCT 3󸀠
ACC Forward 5
󸀠 AGGCAGCTGAGGAAGTTGGCT 3󸀠
Reverse 5󸀠 CGCTGCACAGAGCAGTCACG 3󸀠
ACO Forward 5
󸀠 TGTGACCCTTGGCTCTGTTCT 3󸀠
Reverse 5󸀠 TGTAGTAAGATTCGTGGACCTCTG 3󸀠
Adiponectin receptor-2 Forward 5
󸀠 ACGTTGGAGAGTCATCCCGTA T 3󸀠
Reverse 5󸀠 CTCTGTGTGGATGCGGAAGAT 3󸀠
Apo B Forward 5
󸀠 GCGAGTGGCCCTGAAGGCTG 3󸀠
Reverse 5󸀠 CCGTGGAGCTGGCGTTGGAG 3󸀠
ATGL forward 5
󸀠 TGTGGCCTCATTCCTCCTAC C 3󸀠
Reverse 5󸀠 TCGTGGATGTTGGTGGAGCT 3󸀠
ChREBP Forward 5
󸀠 ACTCAGGGAATACACGCCTACAG 3󸀠
Reverse 5󸀠 TCTTGGTCTTAGGGTCTTCAGGAA 3󸀠
CPT1 Forward 5
󸀠 AGTGACTGGTGGGAGGAATA 3󸀠
Reverse 5󸀠 CTTGAAGTAACGGCCTCTGT 3󸀠
FAS Forward 5
󸀠 GATATTGTCGCTCTGAGGCTGTTG 3󸀠
Reverse 5󸀠 GGAATGTTACACCTTGCTCCTTGC 3󸀠
MTP Forward 5
󸀠 CATTCAGCACCTCCGGACTT 3󸀠
Reverse 5󸀠GATACTGCTGTCACTTTTGAAATCCA 3󸀠
PGC1𝛼 Forward 5
󸀠 CCTGACACGGAGAGTTAAAGGAA 3󸀠
Reverse 5󸀠 GATGGCACGCAGCCCTAT 3󸀠
PPAR𝛼 Forward 5
󸀠 GCAGCTCGTACAGGTCATCA 3󸀠
Reverse 5󸀠 CTCTTCATCCCCAAGCGTAG 3󸀠
SCD1 Forward 5
󸀠 TGGGTTGGCTGCTTGTG 3󸀠
Reverse 5󸀠 GCGTGGGCAGGATGAAG 3󸀠
SREBP1c Forward 5
󸀠 CCTGGTGGTGGGCACTGAAGC 3󸀠
Reverse 5󸀠 GCGTCTGAAGGGTGGAGGGGT 3󸀠
TNF𝛼 Forward 5
󸀠 CCCTCCTGGCCAACGGCATG 3󸀠
Reverse 5󸀠 TCGGGGCAGCCTTGTCCCTT 3󸀠
UCP2 Forward 5
󸀠 AGCATGGTAAGGGACCAGTG 3󸀠
Reverse 5󸀠 CAGTTCTACACCAAGGCTC 3󸀠
tubulin was used as an internal control (1 : 20,000, Sigma).
Then, the membranes were washed with TBST, incubated
with horseradish peroxidase- (HRP-) conjugated secondary
antibodies diluted 1 : 1000, and washed again. Reactions were
developed using an enhanced chemiluminescence detection
system (Pierce ECL Western Blotting Substrate, Thermo Sci-
entific, Rockford, USA). Images were captured using Image-
Quant LAS 400 Mini equipment, and band intensities were
quantified via optical densitometry using ImageJ software.
2.14. Statistical Analysis. Results are presented as the mean
± standard error for the number of determinations (𝑛)
indicated. Statistical analysis was performed using two-
way ANOVA followed by Bonferroni correction. Statistical
significance was defined as 𝑝 ≤ 0.05.
3. Results
3.1. ApoCIII Overexpression Increases Diet-Induced Adipos-
ity. Hypertriglyceridemic apoCIII-overexpressingmice were
compared to control nontransgenic (NTg) littermates follow-
ing consumption of either a LFD or a HFD. Morphometric
and plasma biochemical parameters were assessed (Table 3).
TheHFD increased daily caloric intake, bodymass, andwhite
perigonadal adipose tissue mass but decreased relative liver
mass in both groups. The apoCIII mice fed the HFD showed
greater adiposity accompanied by increased leptin plasma
levels. As expected, there was a genotype-dependent but diet-
independent hyperlipidemic phenotype in the apoCIII mice,
as shown by elevated plasma levels of TG, cholesterol and free
fatty acids (Table 3).
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Table 3: Food intake; body, liver, and adipose tissue masses; and fasting plasma concentrations of lipids, leptin, and inflammatory markers
in NTg and apoCIII mice fed either a low-fat diet (LFD) or a high-fat diet (HFD) for 16 weeks.
LFD HFD
NTg CIII NTg CIII
Food intake (kcal/mouse/day) 15.41 ± 1.2 14.6 ± 0.9 19.6 ± 0.8
∗ 21.8 ± 0.6∗
(7) (7) (5) (5)
Body mass (g) 23.2 ± 0.3 24.0 ± 0.3 29.6 ± 1.1
∗ 29.5 ± 0.9∗
(17) (16) (8) (6)
Liver (%body weight) 3.7 ± 0.0 3.8 ± 0.1 2.9 ± 0.1
∗ 3.2 ± 0.1∗
(17) (17) (8) (8)
Perigonadal WAT (%) 1.2 ± 0.1 1.4 ± 0.1 3.0 ± 0.2
∗ 3.6 ± 0.1∗#
(10) (10) (8) (8)
Plasma triglycerides (mg/dL) 71.4 ± 5.0 780.2 ± 53.6
# 81.5 ± 3.8 668.1 ± 52.8#
(7) (7) (7) (7)
Plasma cholesterol (mg/dL) 122.0 ± 7.8 150.3 ± 11.3 135.1 ± 4.9 199.5 ± 13.2
#
(9) (7) (7) (8)
Nonesterified fatty acids (mEq/L) 0.24 ± 0.01 0.50 ± 0.04
# 0.30 ± 0.03 0.41 ± 0.02#
(10) (8) (6) (5)
Plasma leptin (pg/mL) 635.6 ± 156 526.0 ± 162 1712.8 ± 618
∗ 3033.4 ± 925∗
(9) (7) (6) (7)
Plasma IL6 (pg/mL) 5.7 ± 0.6 6.5 ± 0.9 13.4 ± 0.9
∗ 21.03 ± 2.1∗#
(6) (6) (7) (4)
Plasma C-reactive protein (ng/mL) 320.9 ± 31.2 563.1 ± 73.8
# 405.7 ± 45.8 628.6 ± 39.7#
(9) (7) (7) (8)
Mean ± SEM (𝑛). ∗LFD versus HFD groups; #NTg versus apoCIII mice (𝑝 < 0.05; two-way ANOVA).
Next, we assessed several indicators related to the natu-
ral history of NAFLD, including lipid accumulation, redox
imbalance, inflammation, and cell death.
3.2. Overexpression of ApoCIII Promotes Hepatic Steatosis
and Liver Dysfunction. Overexpression of apoCIII resulted
in increased liver lipid content independent of diet type.
This was observed as macrovesicular steatosis in histological
analyses performed using HE (Figure 1(a)) and Oil Red O
staining (Figure 1(b)) and as increased liver TG content (38%
in the LFD group and 28% in the HFD group) (Figure 1(c)).
Confirming the presence of liver injury, the apoCIII mice
showed increased plasma levels of the hepatic transaminase
AST under both diets and of ALT under the HFD (Figures
1(d) and 1(e)).
3.3. Overexpression of ApoCIII Promotes Glucose Intolerance
and Increases Hepatic Glucose Production following Consump-
tion of a HFD. Disturbed glucose metabolism is associated
with liver steatosis; therefore, we next evaluated glucose
homeostasis in the mice. As shown in Figure 2, HFD
consumption induced glucose intolerance in both groups,
although the effect of the HFD was more potent in the apoC-
III mice (Figure 2(a)), which showed a 12% increase in the
area under the glycemic curve compared to the NTg group.
The ITT results showed no diet or genotype effects (data
not shown). However, in determining the pyruvate-derived
liver glucose production rate (Figure 2(b)), we showed that
the HFD-fed apoCIII mice had increased gluconeogenesis
capacity. Together with the glucose intolerance exhibited
by these mice, these results indicate that hepatic insulin
resistance was present in the apoCIII mice fed the HFD.
3.4. Effects of ApoCIII Overexpression and HFD Consumption
on Intracellular Lipid Metabolism-Related Gene Expression
and Liver VLDL-TG Secretion. To identify the processes driv-
ing the observed increases in liver lipid content, we analyzed
the expression of genes related to lipid uptake, synthesis,
catabolism, and secretion (Figures 3 and 4).We observed that
the mRNA expression of CD36, which is responsible for lipid
uptake, was not significantly modulated by diet or genotype
(Figure 3). In contrast, mRNA expression of ChREBP (car-
bohydrate response element binding protein), a transcription
factor involved in lipogenesis and activated by glucose,
increased only in the livers of the HFD-fed apoCIII mice.
The HFD also increased the mRNA levels of SREBP1c (sterol
response element binding protein) and one of its targets, ACC
(acetyl-CoA carboxylase), independent of genotype. Expres-
sion of stearoyl-CoA desaturase-1 (SCD-1) was markedly
reduced by the HFD (Figure 3(f)).
Expression levels of genes related to lipid catabolism and
secretion are shown in Figure 4. The mRNA level of ATGL
(adipose tissue triglyceride lipase), responsible for initial
TG hydrolysis, was reduced by HFD consumption indepen-
dent of genotype. Levels of CPT1 (carnitine palmitoyl acyl
transferase) and UCP2 (mitochondrial uncoupling protein-
2), which both accelerate fatty acid oxidation, were reduced in
the LFD-fed apoCIII mice and in both HFD groups. PGC1𝛼
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Figure 1: Overexpression of apoCIII promotes hepatic steatosis and dysfunction. NTg and apoCIII mice fed with low-fat (LF) or high-fat
(HF) diets for 16 weeks. Representative liver sections isolated from mice stained with (a) HE and (b) Oil Red O. Note the macrovesicular
lipid deposits, which appear as white spots in the HE-stained tissues (a), and the presence of lipids, which are stained in red (b). (c) Liver
triglyceride content determined by enzymatic assay (𝑛 = 7-8). (d) Plasma concentrations of the transaminases ALT and AST (𝑛 = 5). Data
are expressed as the mean ± SEM. ∗LF versus HF groups; #NTg versus apoCIII mice (𝑝 < 0.05; two-way ANOVA).
(PPAR gamma coactivator-1𝛼 and inducer of mitochondria
biogenesis) levels were reduced by the HFD in both groups.
VLDL assembly for subsequent TG secretion is a complex
process, involving the association of lipids with apoB, which
is mediated by MTP (microsomal triglyceride transfer pro-
tein). We observed a reduction in the mRNA abundance
of MTP under the HFD in both groups, whereas apoB
mRNA was reduced in the apoCIII mice under both diets. In
summary, the HFD (independent of genotype) induced the
expression of lipogenesis-related genes (SREBP1c and ACC)
and decreased the expression of catabolism- and secretion-
related genes (SCD1, ATGL, PGC1𝛼, and MTP), while apoC-
III overexpression (under the LFD) significantly reduced the
expression of the CPT1, UCP2 and apoB100 genes.
To measure the actual liver TG secretion rates under the
above experimental conditions, we performed a direct func-
tional assay, as shown in Figure 5. The results show that
liver VLDL-TG secretion rates increased in the apoCIII-over-
expressing mice regardless of diet and that the HFD reduced
VLDL-TG secretion rates in both apoCIII and NTg mice.
3.5. Overexpression of ApoCIII Increases the Ratio of Oxidized
to Reduced Glutathione in Liver. Diet-induced NAFLD is
associatedwith cell oxidative stress. BecauseGSH is one of the
most abundant reducing power used to maintain cell redox
homeostasis, we measured GSH levels in liver. As shown in
Figure 6, overexpression of apoCIII increased the liver GSSG/
GSH ratio, independent of diet type, although the HFD
exacerbated this effect. Protein carbonylation, which is an
indicator of oxidative damage of proteins, was increased by
the HFD independent of genotype.
3.6. ApoCIII Overexpression Induces Liver Inflammation.
Inflammation is a key event in the pathogenesis of NAFLD.
Therefore, we measured a panel of systemic and liver proin-
flammatory markers in the mice. Increased plasma levels of
the cytokine IL6 were present in both HFD groups, although
greater increases were observed in the apoCIII mice. Another
inflammatory marker, C-reactive protein, was significantly
increased in the apoCIII mice, independent of diet type
(Table 3). Plasma levels of adiponectin, an anti-inflammatory
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Figure 2: Overexpression of apoCIII promotes glucose intolerance and increases glucose hepatic production in mice consuming a high-fat
diet. NTg and apoCIII mice were fed either a low-fat (LF) or high-fat (HF) diets for 16 weeks. (a) Glucose tolerance test results and area under
the curve (AUC) (𝑛 = 7–9). (b) Pyruvate-derived glucose production and area under the curve (AUC) (𝑛 = 6–8). Data are expressed as the
mean ± SEM. ∗LF versus HF groups; #NTg versus apoCIII mice (𝑝 < 0.05; two-way ANOVA).
mediator, were diminished by the HFD in both genotypic
groups (Figure 7(a)).The levels of liver adiponectin receptor 2
were also reduced by the HFD and in the apoCIII mice, inde-
pendent of diet type (Figure 7(b)). Therefore, adiponectin
signaling appears to be hampered both by HFD consumption
and apoCIII overexpression.
The HFD induced elevation of plasma TNF𝛼 levels,
and this effect was more pronounced in the apoCIII mice
(Figure 7(c)). Furthermore, liver TNF𝛼 mRNA levels were
increased in the apoCIII mice, independent of diet type (Fig-
ure 7(d)). Immunohistochemical analysis confirmed these
findings, showing increased expression of the macrophage
marker CD68 and colocalization of macrophages with cell-
surface TNF𝛼 receptors in the livers of the apoCIII mice,
independent of diet type (Figures 7(e) and 7(f)).
The inflammasome pathway appears to be activated in
NAFLD. Activation of this pathway involves the formation
and activation of a protein multicomplex that contains
cysteine-aspartate protease-1 (caspase-1). Activated caspase-1
in turn activates and leads to the subsequent secretion of IL1𝛽.
Unlike the LFD, the HFD increased the levels of activated
(cleaved) caspase-1, although the apoCIII mice exhibited
increases in activated caspase-1 levels regardless of diet (Fig-
ure 8(a)). The same pattern was observed for IL1𝛽: the HFD
increased liver IL1𝛽 levels in both groups, but the apoCIII
mice had higher IL1𝛽 levels independent of diet (Figure 8(b)).
In the plasma, we observed that only the HFD affected IL1𝛽
levels (Figure 8(c)). Immunohistochemical analysis revealed
that IL1𝛽 colocalized with macrophages in the livers of the
apoCIII mice, independent of diet type (Figures 8(d) and
8(e)).
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Figure 3: Effects of apoCIII overexpression and high-fat diet consumption on the expression of lipogenesis-related genes. mRNA expression
levels for (a) CD36, (b) ChREBP, (c) SREBP1c, (d) ACC, (e) FAS, and (f) SCD1 in the livers of NTg and apoCIII mice fed either a low-fat (LF)
or high-fat (HF) diets were analyzed and normalized to 𝛽-actin (𝑛 = 6–8). Data are expressed as the mean ± SEM. ∗LF versus HF group; #NTg
versus apoCIII mice (𝑝 < 0.05; two-way ANOVA). A,BMean values with nonmatching superscript letters are significantly different (𝑝 < 0.05;
ANOVA followed by Bonferroni correction).
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Figure 4: Effects of apoCIII overexpression and high-fat diet consumption on the expression of genes related to lipid catabolism and secretion.
mRNA expression levels for (a) ATGL, (b) CPT1, (c) UCP2, (d) PGC1𝛼 (d), (e) MTP, and (f) APOB100 in the livers of NTg and apoCIII mice
fed either a low-fat (LF) or high-fat (HF) diets and normalized to 𝛽-actin (𝑛 = 6–8). Data are expressed as the mean ± SEM. ∗LF versus HF
group; #NTg versus CIII mice (𝑝 < 0.05; two-way ANOVA). A,BMean values with nonmatching superscript letters are significantly different
(𝑝 < 0.05; ANOVA followed by Bonferroni correction).
Oxidative Medicine and Cellular Longevity 9
LF
0
200
400
600
800
1000
N
et
 p
la
sm
a T
G
 (m
g/
dL
)
30 60 90 120 1500
(min)
0
2
4
6
8
(m
g/
dL
·m
in
−
1
)
CIIINTg
NTg
CIII
#
#
#
(a)
HF
0
200
400
600
800
1000
N
et
 p
la
sm
a T
G
 (m
g/
dL
)
30 60 90 120 1500
(min)
0
2
4
6
8
(m
g/
dL
·m
in
−
1
)
CIIINTg
NTg
CIII
##
#
(b)
Figure 5: Overexpression of apoCIII increases liver VLDL-TG secretion. Net increases in plasma triglyceride concentrations after
intraperitoneal injection of Triton WR 1339 (500mg/kg) and curve slopes (inserts) for NTg and apoCIII mice fed either a low-fat (LF) or
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Figure 6: Effects of apoCIII overexpression and high-fat diet consumption on liver oxidative stress and damage. (a) Liver ratio of oxidized
to reduced glutathione (𝑛 = 7–9) and (b) levels of carbonylated proteins (𝑛 = 6–8) in NTg and apoCIII mice fed either a low-fat (LF) or
high-fat (HF) diets for 16 weeks. Data are expressed as the mean ± SEM. ∗LF versus HF group; #NTg versus apoCIII mice (𝑝 < 0.05; two-way
ANOVA).
3.7. ApoCIII Overexpression Induces Liver Apoptosis. Apop-
tosis is present at a more advanced stage of the disease
(steatohepatitis, NASH), which involves both intrinsic and
extrinsic cell death pathways. As shown in Figure 9(a), the
apoCIII mice exhibited activation of the intrinsic apoptosis
signaling pathway, demonstrated by the decreased Bcl2/Bax
ratio. The HFD also diminished this ratio in the NTg group.
To confirm the occurrence of cell death, we measured the
levels of caspase-3, the final death effector, and counted
apoptotic cells using a TUNEL assay. Cell death was more
prominent in the apoCIII mice (independent of diet) and was
further increased by the HFD as evidenced by the high levels
of active (cleaved) caspase-3 and high number of TUNEL-
positive apoptotic cells (Figures 9(b), 9(c), and 9(d)).
3.8. Fibrate Treatment Resolves ApoCIII-Induced Intracellular
Lipid Accumulation but Not Inflammation. We next investi-
gated whether NASH could be reversed to the same extent
among the different groups of mice. To accomplish this, mice
were treated with fenofibrate during the last 2 weeks of HFD
consumption. By activating PPAR𝛼, this drug modulates the
expression of many genes that regulate lipid metabolism,
mainly by decreasing synthesis and increasing catabolism.
Fibrates are also known to reduce apoCIII expression. As
shown in Table 4, fenofibrate treatment reduced body weight,
adipose tissue weight, and leptin plasma levels in both HFD
groups. Plasma TG, cholesterol, and FFA levels were not
affected by fenofibrate treatment and remained elevated in
the apoCIII mice. Fenofibrate did not alter PPAR𝛼 mRNA
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Figure 7: Effects of apoCIII overexpression and high-fat diet consumption on plasma and liver inflammatorymarkers. (a) Plasma adiponectin
(𝑛 = 7–9), (b) liver adiponectin receptor 2 mRNA (𝑛 = 7–9), (c) plasma TNF𝛼 (𝑛 = 5-6), (d) liver TNF𝛼mRNA (𝑛 = 6–8), (e) quantification
of TNF𝛼 and CD68 colocalized areas (𝑛 = 3), and (f) representative immunofluorescent confocal microscopy images of TNF𝛼 and CD68 in
liver sections from NTg and apoCIII mice fed either a low-fat (LF) or high-fat (HF) diets. Data are expressed as the mean ± SEM. ∗LF versus
HF group; #NTg versus apoCIII mice (𝑝 < 0.05; two-way ANOVA). A,B,CMean values with nonmatching superscript letters are significantly
different (𝑝 < 0.05; ANOVA followed by Bonferroni correction).
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Figure 8: Effects of apoCIII overexpression and high-fat diet consumption on plasma and liver inflammatory markers. (a) Liver cleaved
caspase-1 (𝑛 = 5), (b) liver IL1𝛽𝛽 (𝑛 = 4), (c) plasma IL1𝛽𝛽 (𝑛 = 4-5), (d) quantification of IL1𝛽𝛽 and CD68 colocalized areas, and (e)
representative immunofluorescent confocal microscopy images of IL1𝛽𝛽 and CD68 in liver sections (𝑛 = 3) from NTg and apoCIII mice fed
either a low-fat (LF) or high-fat (HF) diets for 16 weeks. Data are expressed as the mean ± SEM. ∗LF versus HF groups; #NTg versus apoCIII
mice (𝑝 < 0.05; two-way ANOVA).
expression, but it reduced FAS mRNA expression and
increased ACO, CPT1, and UCP2 mRNA expression in both
HFD groups (Table 5). Fenofibrate also markedly reduced
liver TG content. In addition, fenofibrate decreased plasma
levels of the hepatic transaminases AST and ALT, although
AST levels remained elevated in the apoCIII mice (Table 5).
Fenofibrate treatment was also effective in attenuating
both oxidative stress and inflammation (Table 5). GSSG/GSH
ratio and carbonyl content were both reduced by fenofibrate,
although the latter remained elevated in the apoCIII mice.
Additionally, plasma TNF𝛼 levels were reduced by the drug
treatment but remained higher in the apoCIII mice. Plasma
adiponectin levels were not altered by fenofibrate, whereas
the levels of liver adiponectin receptor 2 were significantly
increased only in the NTg mice. Fenofibrate also reduced
plasma levels of IL6, but not C-reactive protein (Table 5).
Levels of cleaved caspase-1 (Figure 10(a)) in the liver
as well as plasma and liver levels of IL1𝛽 (Table 5) were
diminished by treatmentwith fenofibrate.However, liver IL1𝛽
levels (Figure 10(b)) remained elevated in the apoCIII mice
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Figure 9: Effects of apoCIII overexpression and high-fat diet consumption on liver cell death. (a) Ratio between the anti- and proapoptotic
proteins BCL2 and BAX (𝑛 = 7–9), (b) cleaved (activated) caspase-3 (𝑛 = 5-6) and number of apoptotic cells (TUNEL-positive cells), and (c)
representative images and (d) quantification (𝑛 = 3) in NTg and apoCIII mice fed either a low-fat (LF) or high-fat (HF) diets for 16 weeks.
Data are expressed as the mean ± SEM. ∗LF versus HF group; #NTg versus apoCIII mice (𝑝 < 0.05; two-way ANOVA). A,B,ABMean values
with nonmatching superscript letters are significantly different (𝑝 < 0.05; ANOVA followed by Bonferroni correction).
independent of treatment. Fenofibrate also increased the
Bcl2/Bax ratio (Figure 10(c)) and reduced activated caspase-3
levels in both NTg and apoCIII mice compared to nontreated
counterparts. Confirming these results, there was a reduction
in the number of TUNEL-positive cells in both fenofibrate-
treated groups (Figures 10(d) and 10(e)).
4. Discussion
In the present study, we demonstrated that overexpression of
apoCIII results in NAFLD, independent of diet.The develop-
ment of NAFLD was characterized by increases in liver TG
content, oxidative stress, inflammation, and cell death. The
condition was aggravated and additional NAFLD features
were induced, such as impaired glucose tolerance and hep-
atic insulin resistance, in apoCIII mice consuming a HFD.
Furthermore, inflammatory indicators and apoptotic cell
numbers were augmented in the HFD-fed apoCIII mice. As
expected, fenofibrate treatment reversed several of the effects
associated with HFD consumption and apoCIII overexpres-
sion. However, it is important to emphasize that fenofibrate
did not normalize apoCIII-induced inflammatory traits,
such as increased plasma TNF𝛼 levels and augmented liver
TNFr and IL1𝛽 levels. These findings suggest that persistent
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Table 4: Food intake; body, liver, and adipose tissue masses; and fasting plasma concentrations of lipids and leptin in NTg and CIII mice fed
a high-fat diet (HFD) and treated or not with fenofibrate (HFD/F).
HFD HFD/F
NTg CIII NTg CIII
Food intake (kcal/animal/day) 19.6 ± 0.8 20.8 ± 0.6 20.1 ± 0.7 20.1 ± 0.8
(5) (5) (4) (4)
Body weight (g) 28.8 ± 0.5 31.6 ± 2.2 27.4 ± 0.8
$ 28.2 ± 0.3$
(9) (6) (6) (6)
Liver (% body weight) 3.2 ± 0.1 3.0 ± 0.1
# 3.6 ± 0.1$ 3.4 ± 0.1#$
(7) (8) (6) (6)
Perigonadal WAT (%) 3.0 ± 0.3 3.5 ± 0.3 1.8 ± 0.2
$ 2.1 ± 0.4$
(6) (7) (6) (6)
Plasma triglycerides (mg/dL) 83.2 ± 4.9 693.0 ± 28.3
# 59.0 ± 4.7 508 ± 59.6#
(7) (7) (7) (7)
Plasma cholesterol (mg/dL) 132.9 ± 5.2 187.2 ± 14.2
# 154.3 ± 11.6 232.7 ± 30.6#
(6) (6) (6) (6)
Nonesterified fatty acids (mEq/L) 0.33 ± 0.03 0.40 ± 0.01
# 0.25 ± 0.02 0.48 ± 0.05#
(7) (8) (6) (6)
Plasma leptin (pg/mL) 1783.4 ± 143 2011.5 ± 266 644.69 ± 57
$ 704.1 ± 52$
(6) (5) (6) (6)
Mean ± SEM (𝑛). $HFD versus HFD/F groups; #NTg versus apoCIII mice (𝑝 < 0.05; two-way ANOVA).
hypertriglyceridemia might be more relevant to liver inflam-
mation than intracellular lipid accumulation.
A previous study showed that increased plasma apoCIII
concentrations predisposemice to diet-inducedNAFLD [21].
These authors focused on the insulin resistance observed in
this mouse model when fed a HFD. Severe hepatic insulin
resistance was characterized using the hyperinsulinemic-
euglycemic clamp technique and was attributed to increased
hepatic diacylglycerol content and protein kinase C-epsilon
activation and decreased insulin activation of Akt2 [21].
Here, we confirmed that HFD consumption induces insulin
resistancemore severely in apoCIIImice than inNTgmice, as
shown by the simultaneous glucose intolerance and increased
gluconeogenesis that developed in the former group. We also
confirmed a recent find from our group that apoCIII overex-
pression aggravates diet-induced obesity [26].We have previ-
ously shown that apoCIII mice exhibit normal glucose home-
ostasis and insulin secretion when fed a normal diet, and
these parameters were disturbed following acute increases
in plasma FFA levels induced by heparin [27] or HFD con-
sumption [28].
We showed that apoCIII overexpression increases VLDL-
TG secretion regardless of diet type. However, this secretion
was not enhanced enough to avoid the accumulation of lipids
in the livers of the apoCIIImice. Reductions in the expression
of genes related to lipid catabolism (CPT1 and UCP2) were
observed in the apoCIII mice, which may explain, at least
in part, their higher net liver lipid accumulation. The HFD
reduced VLDL-TG secretion rates in both apoCIII and NTg
mice, which explains the exacerbations in lipid accumulation
that were observed in mice fed this diet. Lee et al. [21]
reported increased FFA and TG liver uptake in apoCIII mice
regardless of diet type. Others have found that FFA uptake
from plasma is increased in liver and skeletal muscle but
decreased in adipose tissue in obese subjects with NAFLD
compared to obese subjects with normal intrahepatic triglyc-
eride content [29]. Although we found no differences in
FAT/CD36 mRNA expression between the apoCIII and NTg
mice, it is likely that FFAuptake increased in the apoCIIImice
under both diets due to the greater availability of TG and FFA
in the plasma of these mice. Interestingly, we found that the
HFD induced the expression of ChREBP mRNA specifically
in the apoCIII mice. Hepatic de novo lipogenesis is regulated
through activation of both SREBP-1c [30] and ChREBP [31],
which transcriptionally activate nearly all genes involved in
this process. Thus, lipogenesis may also contribute to liver
steatosis in apoCIII mice. In addition to increased total TG
content, in a previous study, we compared the liver lipidomes
of apoCIII andNTgmice fed a regular diet.We demonstrated
higher incorporation of oleic acid in phosphatidylcholine
and TGs, higher content of phosphatidylinositol-containing
arachidonic acid, and distinct overall FFAprofiles in the livers
of apoCIII mice, which showed elevated relative abundances
of oleic (18 : 1), palmitoleic (16 : 1), arachidonic (20 : 4), mar-
garic (17 : 0), and stearic (18 : 0) acids [32]. It is generally
accepted that, in the natural course of liver disease, lipid
accumulation, either from diet or from de novo lipogenesis,
is the triggering event (first hit of the two-hit hypothesis) that
leads to lipotoxicity in hepatocytes [16, 33]. In hepatocytes,
excessive lipid storage may directly contribute to organelle
failure, including mitochondrial dysfunction and endoplas-
mic reticulum stress and may play a role in hepatic insulin
resistance [34]. We previously examined hepatic oxidative
status in apoCIII mice fed a regular diet. We found cell redox
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Table 5: Plasma indicators of liver injury and inflammation, liver triglyceride content, oxidative stress indicators, and gene expression related
to energy metabolism in NTg and CIII mice fed a high-fat diet (HFD) with or without fenofibrate treatment (HFD/F).
HFD HFD/F
NTg CIII NTg CIII
Plasma AST (U/L) 123.3 ± 9.8 160.6 ± 7.7
# 74.5 ± 13.7$ 98.6 ± 11.8#$
(5) (5) (5) (5)
Plasma ALT (U/L) 77.3 ± 11.4 107.7 ± 12.5
# 35.7 ± 5.8$ 39.9 ± 10.9#$
(5) (5) (4) (4)
Plasma adiponectin (ng/mL) 20.2 ± 0.6 20.13 ± 0.3 19.86 ± 0.5 19.12 ± 0.2
(5) (5) (5) (6)
Plasma TNF𝛼 (pg/mL) 37,51 ± 11.3 301.05 ± 17.5
# 13.3 ± 7.0$ 140.1 ± 7.0#$
(4) (4) (4) (4)
Plasma IL6 (pg/mL) 13.64 ± 1.3
b 26.52 ± 2.1a 14.2 ± 1.8b 14.38 ± 1.4b
(5) (5) (5) (5)
Plasma C-reactive protein (ng/mL) 415.2 ± 44.1 582.6 ± 32.5 586.8 ± 22.1 530.9 ± 29.0
(5) (5) (5) (5)
Plasma IL1𝛽 (pg/mL) 1.00 ± 0.34 1.40 ± 0.51 0.53 ± 0.08 0.54 ± 0.07
(4) (4) (4) (5)
Liver triglycerides (mg/g) 11.36 ± 1.1 14.0 ± 2.6 7.10 ± 0.8
$ 8.66 ± 1.5$
(7) (8) (6) (6)
Liver GSSG/GSH ratio 0.53 ± 0.01 0.54 ± 0.02 0.49 ± 0.01
$ 0.47 ± 0.04$
(6) (6) (6) (6)
Liver protein carbonyl (nmol/mg protein) 15.1 ± 1.5 17.2 ± 2.4
# 7.1 ± 0.5$ 12.2 ± 2.0#$
(6) (7) (6) (6)
Liver mRNA (% control)
PPAR𝛼 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.2 1.1 ± 0.2
(5) (6) (5) (6)
FAS 1.0 ± 0.2 1.2 ± 0.1 0.39 ± 0.1
$ 0.45 ± 0.1$
(8) (5) (5) (5)
CPT1 1.0 ± 0.1 0.62 ± 0.1 1.2 ± 0.2
$ 1.1 ± 0.2$
(8) (8) (6) (6)
ACO 1.0 ± 0.3 1.1 ± 0.1 1.7 ± 0.1
$ 1.4 ± 0.2$
(6) (6) (6) (6)
UCP2 1.0 ± 0.1 0.9 ± 0.1 2.0 ± 0.1
$ 2.0 ± 0.3$
(6) (5) (5) (5)
Adiponectin R2 1.0 ± 0.1
b 0.54 ± 0.05c 1.70 ± 0.2a 0.56 ± 0.1c
(8) (6) (6) (6)
mRNA data normalized to beta-actin. Mean ± SEM (𝑛) $HFD versus HFD/F groups and #NTg versus apoCIII mice (𝑝 < 0.05; two-way ANOVA). a,b,cMean
values with nonmatching superscript letters are significantly different (𝑝 < 0.05, ANOVA followed by Bonferroni correction).
imbalance, evidenced by increased total levels of carbony-
lated proteins and malondialdehydes and elevated GSSG/
GSH ratios in the livers of apoCIII mice compared to NTg
mice [20].Moreover, we found that the origin of this oxidative
stress was associated with higher activities of two oxidases,
NADPH oxidase, and xanthine oxidase, whereas mitochon-
dria actually produced lower amounts of H2O2 due to a mild
uncoupling adaptation mediated by the opening of ATP-
sensitive potassium channels [20, 35]. Here, we confirmed
that the livers of apoCIII mice have lower levels of GSH
regardless of diet type, while consumption of a HFD induced
protein carbonylation in the livers of both apoCIII and NTg
mice.
Recent findings have indicated that inflammation is a key
process for both the initiation and progression of NAFLD.
For instance, knockout of the caspase-1 gene, which blocks
the inflammasome pathway, is sufficient to protect mice from
diet-induced NASH [36]. Accordingly, the absence of inter-
leukin 1𝛼 or 1𝛽 (both targets of caspase-1) inhibits the evolu-
tion of liver steatosis to steatohepatitis and liver fibrosis [37].
In addition, double knockout of TNF𝛼 receptor 1 and 2 pro-
tects mice against liver lipid accumulation and other features
ofNAFLD induced by consumption of amethionine/choline-
deficient diet [38], whereas anti-TNF𝛼 antibody treatment
was shown to decrease lipid content and JNK signaling
pathway in HFD-fed ob/ob mice [39]. Huang et al. [40]
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Figure 10: Effects of fenofibrate treatment on high-fat-diet-induced inflammation and apoptosis. (a) Liver cleaved caspase-1 (𝑛 = 4), (b) liver
IL1𝛽𝛽 (𝑛 = 4), (c) liver BCL2/BAX ratio (𝑛 = 7–9), (d) liver cleaved caspase-3 (𝑛 = 6) and number of apoptotic cells (TUNEL-positive cells),
and (c) representative images and (d) quantification (𝑛 = 3) from NTg and apoCIII mice fed either a low-fat (LF) or high-fat (HF) diets for
16 weeks. Data are expressed as the mean ± SEM. $LF versus HF group; #NTg versus apoCIII mice (𝑝 < 0.05; two-way ANOVA). A,BMean
values with nonmatching superscript letters are significantly different (𝑝 < 0.05; ANOVA followed by Bonferroni correction).
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demonstrated that high-fat or high-sucrose diet-induced ste-
atosis is preventablewhen the liver is depleted of Kupffer cells,
and neutralizing antibodies against TNF𝛼 attenuate Kupffer
cell-induced alterations in hepatocyte lipid metabolism. Our
results support the central role of inflammation in NAFLD.
In the present study, apoCIII mice fed a LFD exhibited a
broad spectrum of liver inflammation, including activation
of the TNF𝛼, inflammasome, and adiponectin pathways.
This inflammation persisted after fibrate treatment, which
resolved intracellular lipid accumulation but did not correct
the levels of proinflammatory effectors (TNF𝛼, TNF𝛼 recep-
tor, IL1𝛽, and low adiponectin-R2).
There are likely multiple origins for the proinflammatory
state in this model. It should be noted that none of the
inflammatory markers/effectors that were measured in this
work are tissue specific. They can be produced locally in
the liver by activated Kupffer cells but are also derived from
activated circulating immune and vascular cells as well as
from adipose tissue, particularly enlarged visceral fat, which
is an important source of many cytokines. Mild to moderate
hypertriglyceridemia in healthy young men has been asso-
ciated with increased concentrations of several biochemical
markers of inflammation and endothelial activation and dys-
function [41]. This hypertriglyceridemia-associated systemic
inflammation can be reversed to varying degrees by admin-
istration of fibrates, resveratrol or omega-3 fatty acids [42–
44]. However, independent of triglyceride levels, apoCIII has
inflammatory and cytotoxic effects [45]. For instance, puri-
fied human apoCIII enhances the attachment of monocyte-
like cells to the human saphenous vein or coronary artery
endothelial cells under both static and laminar shear stress
conditions via induction of VCAM-1 [46]. In addition to
inflammation, elevated circulating apoCIII levels may con-
tribute to beta-cell apoptosis and diabetes [47–49], although
this is controversial [50]. Supporting the finding that apoCIII
is proapoptotic, we recently demonstrated that apoCIII-over-
expressing spleen mononuclear cells present higher rates of
apoptosis in vitro and that apoCIII mice have a reduced
number of blood circulating lymphocytes. Additionally, cyto-
chrome c release into cytosol and caspase-8 activity were both
increased in apoCIII-overexpressingmononuclear cells, indi-
cating that cell death signaling starts upstream of mitochon-
dria but does involve this organelle [51]. Here, we showed
that apoCIII mice exhibit marked increases in apoptotic cell
numbers in the liver under low-fat (2-fold) and high-fat (5-
fold) diets.
In conclusion, our findings show that, in addition to exce-
ssive hepatic lipid accumulation and insulin resistance, apoC-
III overexpression-induced hypertriglyceridemia is associ-
ated with liver inflammation and cell death, which increase
susceptibility to and the severity of diet-induced fatty liver
disease.
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